Content deleted Content added
moved etymology to top (prefacing a comment with "note:" is pretentious) |
moved references + fmt |
||
Line 5:
[[Epidemic]]s of fatal [[pulmonary hypertension]] and heart valve damage associated with anorectic agents have led to the withdrawal of products from the market. This was the case with [[aminorex]] in the [[1960s]], and again in the [[1990s]] with [[fenfluramine]] (''see:'' [[Fen-phen]]). Likewise, association of the related appetite suppressant [[phenylpropanolamine]] with hemorrhagic [[stroke]] led the [[FDA]] to request its withdrawal from the market in the [[United States]] in [[2000]], and similar concerns regarding [[ephedrine]] resulted in an [[FDA]] ban on its inclusion in [[OTC]] products in [[2004]].
In spite of these precedents, numerous related compounds are still marketed today as appetite suppressants. These include [[phentermine]] (Fastin®, Adipex®, Ionamin® and others), [[diethylpropion]] (Tenuate®), [[phendimetrazine]] (Prelu-2®), [[benzphetamine]] (Didrex®) and others. [[Sibutramine]] (Medaria®, Reductil®) is a recent addition, which is used with [[orlistat]] by doctors to control obesity. The new [[Cannabinoids|cannabinoid]] [[receptor]] [[receptor_antagonist|antagonist]] [[Rimonabant]] (Acomplia®) will be available in 2006.
==References==
* Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, Higenbottam T, Oakley C, Wouters E, Aubier M, Simonneau G, Begaud B. ''Appetite-Suppressant Drugs and the Risk of Primary Pulmonary Hypertension''. [[N Engl J Med]] 1996;335:609. [http://content.nejm.org/cgi/content/full/335/9/609 Fulltext]. {{PMID|8692238}}.
* Fishman AP. ''Aminorex to Fen/Phen: An Epidemic Foretold''. Circulation 1999;99:156. [http://circ.ahajournals.org/cgi/content/full/99/1/156 Fulltext]. {{PMID|9884392}}.
==External links==
* [http://healthlink.mcw.edu/article/933126929.html Questions and Answers about appetite suppressant medication treatment from the Medical College of Wisconsin]
[[Category:Pharmacologic agents]]
| |||